Independent Authorised Representative or Distributor: Who Controls Your Malaysian Device Registration
C. Y. Chin, Business Development Director | Infinity Pharmacare | August 2026
A foreign medical device manufacturer cannot register a device in Malaysia under its own name. The application must be made by an establishment, and where the manufacturer is foreign, that establishment is a Malaysian Authorised Representative, who becomes the registrant of record once the Medical Device Authority issues the certificate. If that Authorised Representative is also your distributor, the distributor controls your market access, not you. The one caveat sits inside the Medical Device Act 2012 itself: nothing in Act 737 requires the Authorised Representative and the distributor to be the same entity. That overlap is a commercial choice manufacturers make, not a regulatory default.
What is an Authorised Representative under the Medical Device Act 2012?
An Authorised Representative (AR) must be a Malaysian resident or domiciled person, or a Malaysian constituted company practising principally in Malaysia, under Section 2 of the Medical Device Act 2012. To operate as one, the entity needs a Letter of Authorisation from the foreign manufacturer, GDPMD certification, and an active MeDC@St 2.0+ account, per MDA/GD/0027, 2nd Edition. An establishment licence is mandatory before that AR can import, export, or place a registered device on the market, under Section 15(1) of Act 737. We cover the licence itself in detail in Infinity’s briefing on the MDA Establishment Licence.
None of this is optional scaffolding around your product. It is the legal identity your device registration sits under in Malaysia.
Can a foreign manufacturer register a device in its own name in Malaysia?
No. Under Section 6(1) of the Medical Device Act 2012, a device application must be made by an establishment, and a foreign manufacturer is not, by definition, an establishment capable of applying in Malaysia. Manufacturers coming from jurisdictions where the legal manufacturer files directly, the US and the EU among them, tend to assume the same applies here. It does not. Someone locally constituted has to stand in front of MDA on your behalf, and that someone is your AR.
Who holds the device registration, you or your AR?
Your AR. MDA issues the registration certificate and registration number to the applicant establishment, which for a foreign manufacturer means the AR, under Section 7(1) of Act 737. Your name appears on the dossier as manufacturer. Theirs appears on the certificate as holder.
There is a second exposure worth naming plainly. MDA may cancel a registration based on the conduct or breaches of the establishment that applied for it, under Section 9(1). That means your registration is exposed not only to your device’s own performance record but to your AR’s compliance conduct under the Act, not only your own product’s record. A weak AR is a weak registration, regardless of how clean your product file is.
What does it take to change your Authorised Representative?
This is the mechanic every manufacturer should map before signing an AR agreement, not after a relationship sours.
Change of AR runs through MDA/GD/0041, Change of Ownership for Medical Device Registration. It is device specific, and the guidance states plainly that it is not the NPRA Change of PRH process used on the drug side. It replaces the AR while keeping the same registration number, under Section 1 of MDA/GD/0041.
The new, incoming AR submits the application, under Section 5. Two sets of documents have to land together. From the new AR: an application form, its own establishment licence, a Letter of Authorisation, and an official request letter from the manufacturer. From the current AR: a signed Current AR Declaration Form and surrender of all applicable device certificates, under Sections 4.1 and 4.2.
That second set is the entire story. The current AR’s signed declaration and surrender of certificates are mandatory for the application to count as complete, under Section 4.2, and MDA/GD/0041 is silent on any power MDA holds to proceed over an uncooperative incumbent AR. Section 47 of Act 737 sets up an Appeal Committee, but it covers decisions of the Authority only. It is silent on private disputes between a manufacturer and its AR. We are not implying either outcome here. The silence is the finding, and manufacturers should read it as exactly that, not as a guarantee that MDA will step in, and not as a guarantee that they will not.
Target turnaround is approximately 30 working days, under Section 4, but that clock runs from a complete application. Read the dependency literally: the 30 days do not start until the incumbent AR has signed the declaration and handed over the certificates. An AR who simply does not respond keeps the file incomplete indefinitely, and the 30 day figure never begins to run. This is a separate clock from device classification timelines, which run 14 to 20 working days for Class A and follow a longer combined path for Classes B, C and D. Those figures live in Infinity’s briefing on MDA classification and registration timelines and should not be confused with the AR change timeline here.
The transfer becomes effective on the date MDA approves the application, under Sections 4 and 6. The change of ownership fee is RM 500 per medical device registration ID, paid by the new AR, under Section 6 and Annex A.
What is an Authorised Representative actually responsible for?
Beyond holding the certificate, the AR carries the establishment licence obligations that let the device move at all: import, export, and placing it on the market, under Section 15(1). It also carries vigilance. Mandatory Problem Reporting timelines are codified directly in the Act: 48 hours for a serious threat to public health, 10 days for death, serious deterioration, or risk of recurrence, and 30 days for other reportable incidents, under Section 40(1) and MDA/GD/0014, Section 3.4.1. A follow up investigation report is then due within 30 days of the initial report, under MDA/GD/0014, Section 4.3.
If your AR is also your distributor, your distributor runs your vigilance clock, files your reportable incidents, and decides how fast your team even hears about a problem. That is not a theoretical concern. It is the operational reality of who signs what, and when.
PRH for drugs versus AR for devices: why one partner structure covers neither
Manufacturers running both a drug and a device portfolio into Malaysia often assume one local partner covers both product lines. It does not, and the regulatory text is explicit on the point. Change of AR for devices runs through MDA/GD/0041, which states directly that it is not the NPRA Change of PRH process. Different authority, MDA against NPRA, different guidance document, different application, even where the same distributor and the same manufacturer sit across both product lines. For the drug side, and how a Product Registration Holder can end up controlling your market authorisation the same way an AR controls your device registration, see Infinity’s briefing on the Product Registration Holder in Malaysia. Treat the two workstreams as two separate exposures to negotiate. One partner agreement does not solve both.
How should a device manufacturer choose its AR structure?
Three structures are available, and the legal transfer mechanics under MDA/GD/0041 apply identically across all three. That is the point manufacturers most often get wrong: an independent AR does not get an easier legal pathway out. What changes across the three options is who controls the surrender step in practice, and how much licensing overhead sits on top of the AR role.
| Structure | Legal transfer process | Where control actually sits | Administrative load |
|---|---|---|---|
| Independent AR, separate from your distributor | Same MDA/GD/0041 process, no legal shortcut | Commercial only. Swapping distributors does not touch the registration, since the AR never changes | Standard AR licensing under MDA/GD/0027 |
| Distributor also acting as AR | Same MDA/GD/0041 process, no legal shortcut | The incumbent controls the surrender step in practice, a commercial risk rather than a legal one | Heavier. Since the Single Licence Policy took full effect on 1 July 2024, a distributor acting as AR must hold separate AR and distributor licences, as combined or hybrid licences cannot be renewed |
| Manufacturer’s own Malaysia entity as AR | Same MDA/GD/0041 process if a future change is ever needed | Removes third party control of the surrender step, since the AR sits inside the manufacturer’s own corporate group | Heaviest. The entity must independently meet the Section 2 AR definition and carry its own GDPMD certification, MeDC@St 2.0+ account, and Letter of Authorisation, plus in house vigilance and Mandatory Problem Reporting |
The Single Licence Policy point deserves its own line because it is easy to miss. One role per application applies from 16 February 2024, with full implementation from 1 July 2024. Combined or hybrid licences cannot be renewed past that point. Separate licences are required for each role, AR, importer, distributor, though one entity may hold several separate licences at once, and a refund and transition window runs to the end of 2027. A distributor that has been operating on a combined licence needs to restructure into separate licences to keep acting as your AR at all, regardless of how the relationship performs commercially.
None of this changes the legal weight of MDA/GD/0041. What it changes is your negotiating position and your paperwork load, and both are worth pricing in before you sign, not after you need to exit.
Frequently Asked Questions
Can I register my device in Malaysia without a local partner?
No. Under Section 6(1) of the Medical Device Act 2012, the application must be made by an establishment, and a foreign manufacturer must appoint a Malaysian Authorised Representative to file on its behalf.
Who is named on the Malaysian device registration certificate, the manufacturer or the AR?
The AR. MDA issues the registration certificate and number to the applicant establishment, under Section 7(1) of Act 737, which for a foreign manufacturer is the AR, not the manufacturer.
Can MDA force an uncooperative AR to release my registration?
No documented power exists for this. MDA/GD/0041 is silent on any MDA power to proceed over an uncooperative incumbent AR, and Section 47’s Appeal Committee covers decisions of the Authority only, not private disputes between a manufacturer and its AR.
How long does a change of AR take once we start the process?
Approximately 30 working days, under Section 4 of MDA/GD/0041, but only from a complete application. That clock does not start until the incumbent AR has signed its declaration and surrendered all applicable device certificates.
Does using an independent AR instead of a distributor as AR change the legal transfer process?
No. MDA/GD/0041 applies identically whether your AR is a distributor or an independent entity. The difference an independent AR gives you is commercial, not legal, since a distributor swap never touches the AR or the registration.
This briefing is drawn from primary sources including the Medical Device Act 2012 (Act 737), MDA/GD/0041 Change of Ownership for Medical Device Registration, MDA/GD/0027, MDA/GD/0014, and the Single Licence Policy FAQs. Verify against current official guidance before relying on it.